Meet Our Clinical Collaborators

The collective writings of these respected leaders provide deep medical perspectives and guidance to the management team while‘supporting the tenets of NuView Life Science’s goals.


Clinical Collaborator

Dr. Leonard Gomella is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at Jefferson Medical College, Senior Director Clinical Affairs, Sidney Kimmel Cancer Center, Urology Clinical Service Line Leader, Editor-in-Chief, Canadian Journal of Urology International and immediate Past President, Society of Urologic Oncology.

Originally from New York, Dr. Gomella completed medical school, general surgery and urology training at the University of Kentucky in Lexington, Kentucky. After a Urologic Oncology Fellowship in the Surgery Branch of the National Cancer Institute in Bethesda, Maryland, he joined the faculty of Jefferson Medical College in 1988 and was appointed Chair in 2002. He is also Associate Director for Clinical Affairs for the Kimmel Cancer at Jefferson and Urology Chair for RTOG, serving as lead Urology investigator on multiple national trials. In 2008 he was named Clinical Director of the Jefferson Kimmel Cancer Center Network.

Dr. Gomella is involved in both basic science and clinical research in the development of new diagnostic techniques and treatments for prostate, bladder and kidney cancer through Jefferson’s Kimmel Cancer Center. Dr. Gomella’s team was first to use RT-PCR to detect micro metastasis in patients with prostate cancer, a discovery that led to a new field of investigation in this disease. Dr. Gomella is also recognized as an early contributor to urologic laparoscopy, initiating the program at Jefferson in 1990.


Clinical Collaborator

I am a professor of Radiology and Radiation Oncology at Thomas Jefferson University in Philadelphia. I am also the Director of the laboratories of Radiopharmaceutical research and Molecular Imaging. I obtained my MS and PhD degrees from the University London, England. The major thrust of my research is to develop radiopharmaceuticals for diagnostic and therapeutic applications. I hold 20 granted patents and serve on the editorial board for 14 journals.

My contributions to the field of nuclear medicine and molecular imaging is well recognized by my peers, for which I have received 9 national and International awards, including the Society of Nuclear Medicine’s highest honor, the Benedict Cassen award. I have been elected as President of three international societies, including the Society of Nuclear Medicine and Molecular Imaging. I have been fortunate to have had four of my compounds commercialized and preparations are on the way for two more to be taken into clinical trials.


Clinical Collaborator

Dr. Edouard Trabulsi is a Professor and Vice Chair in the Department of Urology of Sidney Kimmel Medical College at Thomas Jefferson University. He received his Bachelor of Science in Biochemistry cum laude with Distinction in Research from the University of Rochester and completed his medical degree magna cum laude at the State University of New York at Buffalo School of Medicine and Biomedical Sciences. He completed surgery internship, surgery residency, and urology residency at Thomas Jefferson University. He also completed fellowship in urologic oncology and minimally invasive urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York. He specializes in all aspects of urologic oncology and robotic surgery, including prostate cancer, bladder cancer, kidney cancer and testicular cancer. His research interests including advanced imaging for prostate and bladder cancer, including enhanced ultrasound and novel PET imaging, as well as appropriate use of postoperative radiotherapy after radical prostatectomy.
Dr. Trabulsi is Director of the Division of Urologic Oncology in the Department of Urology of Thomas Jefferson University, and Co-Director of the Genitourinary Multidisciplinary Cancer Center at Kimmel Cancer Center and the Jefferson Prostate Diagnostic Center at Thomas Jefferson University. He is the Genitourinary Cancer Multidisciplinary Group Team leader for clinical trials. He previously served as Cancer Liaison Physician for Thomas Jefferson University Hospital for the American College of Surgeons Commission on Cancer. He also has served on several national committees of the American Urologic Association (AUA), including the Education Council, the Resident Core Curriculum Committee and the Legislative Affairs Committee. He is a former President of the Mid-Atlantic Section of the AUA, and just completed service on the Board of Directors for the Society of Urologic Oncology. He is a member of the American Urologic Association, the American College of Surgeons, the American Society of Clinical Oncology, the Society of Urologic Oncology, the American Medical Association, the American Association of Cancer Research and the American College of Health Care Executives.


Clinical Collaborator

Dr. Gil Padula currently serves at Chief Medical Officer at University Hospitals St. John Medical Center. He has over 20 years of progressive leadership experience in oncology and in health care. With over 50 presentations and publications in the scientific literature, Dr. Padula has a national reputation as an innovative radiation oncologist. He has designed, accrued, and published on national-level clinical trials that have altered the way we take care of our patients. In fact, he is Co-Chair of a national clinical trial on prostate cancer survivorship that has been funded by the National Cancer Institute (NCI).

During his career, he has been the recipient of a Federal 10 million-dollar grant from the NCI and he led an 11-heatlh system research consortium that has gone on to be a national leader in clinical trial accrual and implementation. Dr. Padula serves on several prestigious committees of the cancer cooperative groups where he has a special interest in advancing the way cancer care is delivered. He looks forward to working with NuView in developing the latest, most advanced patient-centric theranostics platforms.


Clinical Collaborator

Albert S. DeNittis MD, MS, obtained his Master’s degree in Molecular and Developmental Biology at Rutgers University. Dr. DeNittis then earned his medical degree from Rutgers -Robert Wood Johnson Medical School, and subsequently, completed his residency training in Radiation Oncology at the Hospital of the University of Pennsylvania.

Dr. DeNittis currently serves as Chief of Radiation Oncology at Lankenau Medical Center at Main Line Health. Since joining he has created many programs and has spearheaded cutting edge research with investigator initiated trials. He was one of the first in the country to treat and publish data on linac based stereotactic body radiotherapy using 5 fraction treatments for men with prostate cancer. Also he is part of a rectal cancer treatment team which was awarded one of 12 rectal cancer centers of excellence in the entire nation. This led to Dr. DeNittis being awarded a grant through the National Cancer Institute to be the Principal Investigator (PI) for the National Community Oncology Research Program (NCORP) of the Mainline Health System. This was one of 34 such programs in the country. Since then he is now PI for NRG Oncology for Main Line Health.

Dr. DeNittis also serves on many national committees through the NRG oncology. He is on the NCORP steering, cancer prevention and control committee and membership committees. Recently in 2017 he was elected to the anal/rectal task force to the NCI. He is responsible for clinical trial development nationally. He is interested in theragnostics and wants to use his experience to help develop new treatment strategies for all cancers as part of NuView.

All of his efforts have led to an extensive list of publications, and over 100 presentations at national meetings. He has also coauthored 7 book chapters, four of which have been Principles and Practice of Radiation Oncology, the specialties premier text book. His achievements have earned him a clinical Professor at the Lankenau Institute for Medical Research and he is a member of Thomas Jefferson University cancer center in Philadelphia. He is also a fellow in the College of Physicians of Philadelphia. Regionally he has been Philadelphia Top Doc for over 12 years.

Dr. DeNittis is currently a season ticket holder to the Philadelphia Eagles, and loves to travel.


Clinical Collaborator

Dr. Wassman has pioneered the introduction of genetic testing and personalized medicine for over 30-years. His focus has been on the translation and delivery of cutting-edge diagnostic technology to clinical service in the areas of reproductive medicine, rare cell/non-invasive diagnostics, and Next Generation DNA sequencing spanning clinical disciplines of reproductive genetics, cancer and companion diagnostics, and neurodevelopmental disabilities including autism.

He has served as Chief Medical Officer for multiple companies in this space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics, Alfigen. He has co-founded several successful ventures, and served as a consultant to a wide variety of entities ranging from clinical laboratories, IVD and Biotech companies, investor groups, regulatory agencies, and legal firms. Currently he serves as a senior executive advisor to a number of start-ups and other clients.

He is a graduate of Yale University and Albany Medical College and Board Certified in Pediatrics and Medical Genetics.

Clinical Collaborators